TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,210.10▼ 7.59%TCS₹2,082.30▼ 8.27%HDFCBANK₹704.70▼ 0.82%ICICIBANK₹1,331.40▼ 6.73%INFY₹1,002.20▼ 7.84%HINDUNILVR₹1,880.00▼ 4.08%ITC₹263.85▲ 0.13%SBIN₹951.50▼ 5.41%BHARTIARTL₹1,822.80▼ 1.68%KOTAKBANK₹429.30▲ 1.71%LT₹3,736.00▼ 6.58%AXISBANK₹1,233.30▼ 2.58%ASIANPAINT₹2,382.70▼ 4.73%MARUTI₹11,463.00▼ 10.16%AAPL$333.63▲ 4.27%MSFT$529.30▲ 5.92%GOOGL$347.68▲ 2.72%AMZN$256.29▼ 0.86%NVDA$239.24▲ 3.85%META$738.88▲ 19.80%TSLA$380.68▲ 7.51%BRK-B$505.54▼ 0.10%JPM$331.28▼ 7.63%V$370.64▼ 1.18%
RELIANCE₹1,210.10▼ 7.59%TCS₹2,082.30▼ 8.27%HDFCBANK₹704.70▼ 0.82%ICICIBANK₹1,331.40▼ 6.73%INFY₹1,002.20▼ 7.84%HINDUNILVR₹1,880.00▼ 4.08%ITC₹263.85▲ 0.13%SBIN₹951.50▼ 5.41%BHARTIARTL₹1,822.80▼ 1.68%KOTAKBANK₹429.30▲ 1.71%LT₹3,736.00▼ 6.58%AXISBANK₹1,233.30▼ 2.58%ASIANPAINT₹2,382.70▼ 4.73%MARUTI₹11,463.00▼ 10.16%AAPL$333.63▲ 4.27%MSFT$529.30▲ 5.92%GOOGL$347.68▲ 2.72%AMZN$256.29▼ 0.86%NVDA$239.24▲ 3.85%META$738.88▲ 19.80%TSLA$380.68▲ 7.51%BRK-B$505.54▼ 0.10%JPM$331.28▼ 7.63%V$370.64▼ 1.18%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸PACB

Pacific Biosciences of California, Inc. - Common Stock

NASDAQ
$2.70
▲ $1.35 (+100.0%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 06 Oct 2026
H $3.44L $1.07+114.3%
$3.44$2.97$2.49$2.02$1.54$1.07$2.7
RSI (14)
Intraday · 15-minSell-20RSI 49DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Strong buy+45
RSI (14)80
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
$1.25
Resistance
$3.44
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-01-02 → 2026-10-06

Strategy return
+6.1%
Buy & hold
+46.7%
Trades
7
Win rate
14%

$100,000.00 invested would be worth $106,116.66 (+6.1%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Pacific Biosciences of California, Inc.· Medical Devices

source: yahoo

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Sector
Healthcare
Industry
Medical Devices
Employees
485
Headquarters
Menlo Park, United States
www.pacb.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:— Neutral1↑ · 1↓ · 6–
  • PacBio Sinks 8% as TychoBio Endorses Its “Highest Quality Biological Data” – the Real Story Is More Complicated▼ Negative
    TIKR · 06 Oct 2026
  • Pacific Biosciences of California, TychoBio Collaborate to Generate Full-Length RNA Data for AI Model Training— Neutral
    MT Newswires · 06 Oct 2026
  • PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics— Neutral
    GlobeNewswire · 06 Oct 2026
  • RSI is 80 — overbought, which some traders treat as extended.
  • Educational technical indicators — not investment advice. TradeOrgs does not place trades.

    Why PacBio (PACB) Stock Is Trading Up Today
    — Neutral
    StockStory · 06 Oct 2026
  • Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts▲ Positive
    Zacks · 02 Oct 2026
  • 3 Biotech Stocks Put Traders Are Targeting Today— Neutral
    Schaeffer's Investment Research · 01 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.